The mechanism is solid. The clinical data confirms the direction.
A 2014 double-blind, randomized, placebo-controlled trial published in Skin Pharmacology and Physiology supplemented 69 women aged 35–55 with either 2.5g or 5g of collagen hydrolysate daily for 8 weeks. The treatment groups showed statistically significant improvements in skin elasticity versus placebo, with effects peaking at 4 weeks and maintained through the 8-week endpoint. A 4-week follow-up after cessation showed partial return toward baseline, consistent with the mechanism requiring ongoing fibroblast stimulation.
A 2015 study in the same journal specifically measured skin hydration and dermal collagen density via ultrasound in 105 women over 8 weeks. The collagen peptide group showed significant increases in both measures compared to placebo.
Multiple subsequent trials across different formulations and populations have produced consistent findings: improvements in skin elasticity, hydration, and roughness at the 8–12 week mark with daily supplementation in the 2.5–10g range. Effect sizes are moderate — this is not a dramatic transformation, but the signal is reproducible and the mechanism explains it.
The skeptic's legitimate remaining concern: most of this research is industry-funded. This is true and worth noting. However, the mechanistic data (plasma peptide detection, in vitro fibroblast studies) is independent of industry funding, and the clinical findings have been replicated across multiple manufacturers and formulations. The effect appears real, if modest.